CAS Number129101-54-8
Synonyms3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate 2,3-dihydroxybutanedioate (1:1); RivastigMine L-Tartrate; Rivastigmine Tartrate Salt; N-Ethyl-N-methylcarbamic Acid 3-[(S)-1-(Dimethylamino)ethyl]phenyl Ester L-Tartrate; Rivastigmine; (S)-3-(1-(Dimethylamino)ethyl)phenyl ethyl(methyl)carbamate (2R,3R)-2,3-dihydroxysuccinate; Rivastigmine Tartrate; 3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate 2,3-dihydroxybutanedioate (salt); (2R,3R)-2,3-Dihydroxybutandisäure--3-[(1S)-1-(dimethylamino)ethyl]phenyl-ethyl(methyl)carbamat(1:1); 3-[(S)-1-(Dimethylamino)ethyl]phenyl N-Ethyl-N-methylcarbamate L-Tartrate; Rivastigmine hydrogen tartrate; Rivastigmine (tartrate)
Molecular FormulaC18H28O8N2
Molecular Weight400.43
Purity98%
Boiling Point316.2ºC at 760 mmHg
Melting Point123-1250C
AppearanceWhite to off-white powder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 129101-54-8 |
| Catalog No. | 2A-9012323 |
| Chinese Name | 酒石酸卡巴拉汀 |
| Synonyms | 3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate 2,3-dihydroxybutanedioate (1:1); RivastigMine L-Tartrate; Rivastigmine Tartrate Salt; N-Ethyl-N-methylcarbamic Acid 3-[(S)-1-(Dimethylamino)ethyl]phenyl Ester L-Tartrate; Rivastigmine; (S)-3-(1-(Dimethylamino)ethyl)phenyl ethyl(methyl)carbamate (2R,3R)-2,3-dihydroxysuccinate; Rivastigmine Tartrate; 3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate 2,3-dihydroxybutanedioate (salt); (2R,3R)-2,3-Dihydroxybutandisäure--3-[(1S)-1-(dimethylamino)ethyl]phenyl-ethyl(methyl)carbamat(1:1); 3-[(S)-1-(Dimethylamino)ethyl]phenyl N-Ethyl-N-methylcarbamate L-Tartrate; Rivastigmine hydrogen tartrate; Rivastigmine (tartrate) |
| Molecular Formula | C18H28O8N2 |
| Molecular Weight | 400.43 |
| Purity | 98 |
| Boiling Point | 316.2ºC at 760 mmHg |
| Melting Point | 123-1250C |
| Appearance | White to off-white powder |
| Water Solubility | Soluble in: methanol |
| Storage Condition | -20°C Freezer |
| Application | Rivastigmine tartrate is a cholinesterase inhibitor with an IC50 of 5.5 uM. It also inhibits butyrylcholinesterase and acetylcholinesterase. |
| HTC | 2942000000 |
| MDL Number | MFCD03700731 |
| SMILES | CCN(C)C(=O)Oc1cccc(C(C)N(C)C)c1.O=C(O)C(O)C(O)C(=O)O |
| InChI | InChI=1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m00/s1 |
| InChI Key | GWHQHAUAXRMMOT-MBANBULQSA-N |
| Hazard Symbols | Transport |
| MSDS | msds/12323_1_129101_54_8.pdf |
| Bioactivity | Rivastigmine tartrate, an cholinesterase inhibitor(IC50= 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesteraseIC50 value: 5.5 uMTarget: AChERivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting. The drug is eliminated through the urine, and appears to have relatively few drug-drug interactions. Rivastigmine, a cholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase. It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain chemical acetylcholine. Related Catalog Signaling Pathways >> Neuronal Signaling >> AChE Research Areas >> Neurological Disease References [1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805. [2]. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 Jul-Aug;20(4):634-47. [3]. Stryjer R, Ophir D, Bar F et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012 Jul-Aug;35(4):161-4. [4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42. Chemical & Physical Properties Boiling Point 316.2ºC at 760 mmHg Melting Point 123-1250C Molecular Formula C18H28N2O8 Molecular Weight 400.423 Flash Point 145ºC Exact Mass 400.184570 PSA 147.84000 LogP 0.63710 Vapour Pressure 0.000416mmHg at 25°C InChIKey GWHQHAUAXRMMOT-MBANBULQSA-N SMILES CCN(C)C(=O)Oc1cccc(C(C)N(C)C)c1.O=C(O)C(O)C(O)C(=O)O Storage condition -20°C Freezer |
| Use of | Rivastigmine tartrate, an cholinesterase inhibitor(IC50= 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesteraseIC50 value: 5.5 uMTarget: AChERivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting. The drug is eliminated through the urine, and appears to have relatively few drug-drug interactions. Rivastigmine, a cholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase. It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain chemical acetylcholine. Properties Articles27 Name rivastigmine tartrate Synonym More Synonyms Rivastigmine (tartrate) Biological Activity Description Rivastigmine tartrate, an cholinesterase inhibitor(IC50= 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesteraseIC50 value: 5.5 uMTarget: AChERivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting. The drug is eliminated through the urine, and appears to have relatively few drug-drug interactions. Rivastigmine, a cholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase. It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain chemical acetylcholine. Related Catalog Signaling Pathways >> Neuronal Signaling >> AChE Research Areas >> Neurological Disease References [1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805. [2]. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 Jul-Aug;20(4):634-47. [3]. Stryjer R, Ophir D, Bar F et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012 Jul-Aug;35(4):161-4. [4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42. Chemical & Physical Properties Molecular Formula C18H28N2O8 Exact Mass 400.184570 PSA 147.84000 LogP 0.63710 InChIKey GWHQHAUAXRMMOT-MBANBULQSA-N |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Danger Regulations: - International Maritime Transport Danger Regulations: - 14.2 United Nations shipping name European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Danger Regulations: - International Maritime Transport Danger Regulations: - 14.4 Package group European Land Transport Danger Regulations: - International Maritime Transport Danger Regulations: - 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Transport Danger Regulations Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Ribavirin | 36791-04-5 | 2A-9012297 |
| Rifabutin | 72559-06-9 | 2A-0201665 |
| Risedronate sodium | 115436-72-1 | 2A-9012314 |
| Ritonavir | 155213-67-5 | 2A-9012321 |
| Rivastigmine | 123441-03-2 | 2A-9012322 |
| Rofecoxib | 162011-90-7 | 2A-9012330 |
| Rolitetracycline | 751-97-3 | 2A-9012333 |
| Rosiglitazone | 122320-73-4 | 2A-9012344 |
| Rosuvastatin | 287714-41-4 | 2A-9012346 |
| Rosuvastatin calcium | 147098-20-2 | 2A-9012347 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS